Regenxbio (NASDAQ: RGNX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Regenxbio reported 5 open-market sales of 78,927 shares ($939,970) and 2 open-market purchases of 102,603 shares ($949,541), by 2 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Regenxbio shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
1 November 2026	Christmas Patrick J.	Chief Strategy & Legal Officer	Grant or award	+34,722	—	240,690	Form 4
1 November 2026	Pakola Steve	Chief Medical Officer	Grant or award	+34,722	—	240,263	Form 4
1 November 2026	Chan Mitchell	Chief Financial Officer	Grant or award	+24,305	—	147,120	Form 4
1 November 2026	Malzahn Craig	Chief Technology Officer	Grant or award	+27,777	—	109,737	Form 4
1 September 2026	Chan Mitchell	Chief Financial Officer	Shares withheld for tax	−4,902	$9.32	122,815	Form 4
1 September 2026	Malzahn Craig	Chief Technology Officer	Shares withheld for tax	−234	$9.32	81,960	Form 4
27 August 2026	Ciongoli Gregory Austin	Director	Open-market purchase	+53,407	$9.36	118,035	Form 4
26 August 2026	Ciongoli Gregory Austin	Director	Open-market purchase	+49,196	$9.14	64,628	Form 4
25 August 2026	Ciongoli Gregory Austin	Director	Grant or award	+15,432	—	15,432	Form 4
1 August 2026	Christmas Patrick J.	Chief Strategy & Legal Officer	Shares withheld for tax	−4,699	$9.69	205,968	Form 4
1 August 2026	Pakola Steve	Chief Medical Officer	Shares withheld for tax	−7,468	$9.69	205,541	Form 4
2 July 2026	Pakola Steve	Chief Medical Officer	Option exercise	+2,161	$7.86	215,170	Form 4
2 July 2026	Pakola Steve	Chief Medical Officer	Open-market sale	−2,161	$13.64	213,009	Form 4
1 July 2026	Simpson Curran	Chief Executive Officer	Shares withheld for tax	−6,818	$13.09	338,053	Form 4
1 July 2026	Pakola Steve	Chief Medical Officer	Option exercise	+36,725	$7.86	249,734	Form 4
1 July 2026	Pakola Steve	Chief Medical Officer	Open-market sale	−36,725	$12.86	213,009	Form 4
30 June 2026	Simpson Curran	Chief Executive Officer	Grant or award	+1,453	$10.18	344,871	Form 4
29 June 2026	Pakola Steve	Chief Medical Officer	Open-market sale	−19,608	$11.04	213,009	Form 4
29 May 2026	Migausky George V	Director	Grant or award	+9,807	—	28,861	Form 4
29 May 2026	Karabelas Argeris N	Director	Grant or award	+9,807	—	28,861	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Regenxbio page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.